Fig. 1

BGI detection kit shows superior performance over the Norgen kit. a Analysis of four negative and four positive patient samples extracted with either the Qiagen RNeasy or Norgen RNA isolation kits using the Norgen RT-qPCR detection system with N1 primer/probe sets. Samples L015, L018 and L019 are the mean ± range of technical duplicates run independently on two separate plates, other samples were analyzed once. A paired t-test was used to compare Norgen versus Qiagen extractions. b Analysis of two positive patient samples extracted with the BGI, Norgen (Nor) or Invitrogen Purelink (Pure) RNA isolation kits using the Norgen (N1 or N2 primers/probes) or BGI RT-qPCR detection systems. Mean ± std dev of the same sample run on three (BGI & Norgen extractions) or two (Purelink extraction) separate plates. c Analysis of additional patient samples using the Norgen (N1 or N2 primers) or BGI detection systems. Mean ± range of the same samples run independently on two separate plates. d Comparison of Ct values from original clinical diagnosis (Seegene Allplex RdRp and N genes) and data obtained with the BGI or Norgen detection systems. e ROC curves comparing performance of BGI versus Qiagen RNeasy extraction kits and BGI versus Norgen RT-qPCR detection kits on larger cohort of 29 positive and 30 negative samples. n/a: not applicable. f Comparison of Ct values from original clinical diagnosis (Seegene Allplex RdRp and N genes) and data obtained with the BGI or Norgen detection systems in the larger cohort of 29 positive samples. Horizontal dotted line indicates Ct threshold for positive clinical detection and vertical dotted line indicates Ct threshold for positive detection using the BGI or Norgen systems. Note, that R² and slope calculations include only samples that were detected with Ct < 40. g Detection limit determination using the BGI or Norgen detection systems shown as the number of positives/total number of wells. Concentrations are in copies/µl in the standard. N/D: not determined